[Disease modifying anti-rheumatic drugs(DMARDs)].
Several kinds of disease modifying anti-rheumatic drugs (DMARDs) can be utilized for the treatment of patients with rheumatoid arthritis (RA) to expect the prevention of joint damage progression and the improvement of quality of life. However, the methodology for the use of DMARDs is still controversial. On the basis of our prospective study, earlier introduction of DMARDs can be more efficient for the suppression of active disease. Thus, for the patients with more than three swollen joints, high ESR and CRP, immediate prescription of DMARD is recommended. And if these situation will not change even 6 months after starting the therapy, we should make all possible efforts to lead patients into remission using DMARD or corticosteroids, which would prevent patients from disability of joint function and thus would improve the quality of life of patients with early RA.